A visual and narrative timeline of US FDA milestones for Transcranial Magnetic Stimulation (TMS) devices
- PMID: 34775141
- PMCID: PMC8864803
- DOI: 10.1016/j.brs.2021.11.010
A visual and narrative timeline of US FDA milestones for Transcranial Magnetic Stimulation (TMS) devices
Conflict of interest statement
Declarations of competing interest SLC: none. The City University of New York holds patents on brain stimulation with MB as inventor. MB has equity in Soterix Medical Inc. MB consults, received grants, assigned inventions, and/or serves on the SAB of Boston Scientific, GlaxoSmithKline, Biovisics, Mecta, Lumenis, Halo Neuroscience, Google-X, i-Lumen, Humm, Allergan (Abbvie). MB is supported by grants from Harold Shames and the National Institutes of Health: NIH-NIDA UG3DA048502, NIH-NIGMS T34GM137858, NIH-NINDS 1R01NS112996, NIH-NINDS 1R01NS101362, NIH-NIMH 1R01MH111896, and NIH-NINDS 1R01NS095123. BWB is a named inventor on brain stimulation patents assigned to the Medical University of South Carolina, owns stock in Bodhi NeuroTech, Inc., and serves as a consultant to companies that commercialize brain stimulation technology. BB is funded by the NIH under grants 5P20GM109040-08, 1R43DA050360-01, 5P2CHD086844-05, and 1P50DA046373-01A1. MSG served as a Journal Editor for Elsevier Press and as a Data Safety Monitoring Board member for Microtransponder Neuronetics, and is a member of the BrainsWay SAB.
Figures
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
